New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - erythromycin lactobionate 1.49 g equivalent to 1 g erythromycin;   - powder for infusion - 1 g - active: erythromycin lactobionate 1.49 g equivalent to 1 g erythromycin   - upper respiratory tract infections caused by streptococcus pyogenes (group a beta haemolytic streptococci); lower respiratory tract infections caused by streptococcus pyogenes (group a betahaemolytic streptococci); skin and skin structure infections caused by streptococcus pyogenes.

United States - English - NLM (National Library of Medicine)

hospira, inc. - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin 500 mg in 10 ml - erythrocin lactobionate-iv (erythromycin lactobionate for injection, usp) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae  (diplococcus pneumoniae);  haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci);

United States - English - NLM (National Library of Medicine)

exela pharma sciences, llc - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin lactobionate for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus

United States - English - NLM (National Library of Medicine)

nexus pharmaceuticals inc. - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin lactobionate for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - erythromycin lactobionate, quantity: 1.49 g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment).,? diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.,? acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythromycin panpharma (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin.,? before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immuno-fluorescence or dark field) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.,? legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - erythromycin lactobionate 1000mg;   - powder for injection - 1000 mg - active: erythromycin lactobionate 1000mg  

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - erythromycin lactobionate 300mg;   - powder for injection - 300 mg - active: erythromycin lactobionate 300mg  

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

rebel distributors corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s